YSPSL for Prevention of Delayed Graft Function Part B
Public ClinicalTrials.gov record NCT00298168. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant delayed graft function (DGF). PSGL-1 is a ligand for P-, E-, and L-selectin. It has been reported that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models to reduce both cytokines and tissue damage associated with ischemia reperfusion and to improve renal function post-transplant. Therefore, the current phase I/II clinical study is designed to assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients undergoing cadaveric kidney transplants and to determine a dose for future pivotal studies.
Study identification
- NCT ID
- NCT00298168
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Aug 31, 2007
- Completion
- Nov 30, 2007
- Last update posted
- Jan 28, 2008
2006 – 2007
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dumont-UCLA Transplant Center | Los Angeles | California | 90095 | — |
| California Pacific Medical Center Department of Transplantation | San Francisco | California | 94115 | — |
| University of Colorado Health Sciences Center | Denver | Colorado | 80262 | — |
| Shands Hospital at University of Florida | Gainesville | Florida | 32610 | — |
| Lifelink Foundation | Tampa | Florida | 33606 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Tulane University Hospital & Clinic | New Orleans | Louisiana | 70112 | — |
| Henry Ford Hospital Transplant Institute | Detroit | Michigan | 48202 | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| Westchester Medical Center, New York Medical College | Hawthorne | New York | 10532 | — |
| University of Cincinnati, Department of Internal Medicine | Cincinnati | Ohio | 45267 | — |
| Methodist Healthcare University Hospital | Memphis | Tennessee | 38104 | — |
| Baylor University Medical Center Transplantation Services | Dallas | Texas | 75246 | — |
| The Methodist Hospital | Houston | Texas | 77030 | — |
| University of Texas, Organ Transplantation | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00298168, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2008 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00298168 live on ClinicalTrials.gov.